BioSpace News Archive

Advanced BioMatrix has acquired the HyStem® line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan.

Recipharm AB, through its directly wholly-owned subsidiary Recipharm Holdings Limited, published an offer document setting out the full terms and conditions of its recommended cash offer to acquire the entire issued and to be issued share capital of Consort Medical plc .

CSafe experts will be on hand to demonstrate the company’s Cell & Gene thermal shipping solution at the Phacilitate Leaders World conference in Miami January 21-24.

The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.

Novelion Therapeutics Inc. announced that the implementation of the Company’s voluntary liquidation commenced at 5:00 p.m. Pacific Time, January 16, 2020.

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Potassium Citrate Extended-Release Tablets USP, 10 mEq and 15 mEq.

Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the second

Medtronic is being recognized for the Medtronic Women’s Network and Women in Science and Engineering initiatives, key drivers in the company’s overall Inclusion and Diversity strategy.

Adlon Therapeutics L.P. and Purdue Pharma L.P. today announced that six posters highlighting PRC-063 data as well as research on real-world treatment patterns and patient preferences will be presented at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C.

All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.